Skip to main content

PRGO

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

PRGO Price
Price Chart

Forward-looking statistics

Beta
0.71
Risk
39.86%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees7K
Market cap$3.7B

Fundamentals

Enterprise value$7.1B
Revenue$4.3B
Revenue per employee
Profit margin-4.16%
Debt to equity87.89

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$1.20
Dividend per share$1.10
Revenue per share$31.49
Avg trading volume (30 day)$28M
Avg trading volume (10 day)$26M
Put-call ratio

Macro factor sensitivity

Growth+2.1
Credit+3.0
Liquidity-0.4
Inflation-0.8
Commodities-0.2
Interest Rates-0.5

Valuation

Dividend yield4.08%
PEG Ratio8.72
Price to sales0.86
P/E Ratio8.72
Enterprise Value to Revenue1.64
Price to book0.86

Upcoming events

Next earnings dayFebruary 28, 2025
Next dividend day
Ex. dividend dayMay 30, 2025

News

Should Value Investors Buy Perrigo (PRGO) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research (July 9, 2025)
Trump Tariffs Could Have 'Significant Impact' On Perrigo Earnings, Says JP Morgan

J.P. Morgan say s Perrigo Company plc's  PRGO first-quarter 2025 earnings will be dominated by commentary on the potential impact of tariffs. The analyst says, 'Tariffs could potentially have a significant impact on PRGO's near-term earnings.

Benzinga (April 21, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free